2022
DOI: 10.3960/jslrt.21018
|View full text |Cite
|
Sign up to set email alerts
|

Bendamustine-induced rash is associated with a favorable prognosis in patients with indolent B-cell lymphoma

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1

Citation Types

0
1
0

Year Published

2022
2022
2022
2022

Publication Types

Select...
1

Relationship

0
1

Authors

Journals

citations
Cited by 1 publication
(1 citation statement)
references
References 20 publications
0
1
0
Order By: Relevance
“…The incidence of rash in our study was nearly 22%, consistent with the previously reported rate of 15% to 25%, 4,5 but lower than in the recent review of patients with iNHL treated with bendamustine where rash was reported in 41.5%. Patients who developed rashes after bendamustine typically had a history of allergy, localized stage and had first line BR therapy as compared with the ones without rashes 18 …”
Section: Discussionmentioning
confidence: 99%
“…The incidence of rash in our study was nearly 22%, consistent with the previously reported rate of 15% to 25%, 4,5 but lower than in the recent review of patients with iNHL treated with bendamustine where rash was reported in 41.5%. Patients who developed rashes after bendamustine typically had a history of allergy, localized stage and had first line BR therapy as compared with the ones without rashes 18 …”
Section: Discussionmentioning
confidence: 99%